Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2185-2188

  Van Baelen, Kurt ^a   Salzwedel, Karl ^b   Rondelez, Evelien ^a   Van Eygen, Veerle ^a   De Vos, Stephanie ^a   Verheyen, Ann ^a   Steegen, Kim ^a   Verlinden, Yvan ^a   Allaway, Graham P ^b   Stuyver, Lieven J ^a  

^a Virco BVBA   (Belgium)

^b Panacos Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVIRIMAT; GAG PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PEPTIDES; PHENOTYPE; POLYMORPHISM, GENETIC; SEQUENCE ALIGNMENT; SUCCINATES; TRITERPENES;

EID: 66149150956     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01650-08     Document Type: Article

References (11)

1. Adamson, C. S., S. D. Ablan, I. Boeras, R. Goila-Gaur, F. Soheilian, K. Nagashima, F. Li, K. Salzwedel, M. Sakalian, C. T. Wild, and E. O. Freed. 2006. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (bevirimat). J. Virol. 80:10957-10971.
2. Castillo, A., C. Adamson, J. Doto, A. Yunus, C. Wild, D. Martin, G. Allaway, E. Freed, and K. Salzwedel. 2006. Genotypic analysis of the Gag-SP1 cleavage site in patients receiving the maturation inhibitor PA-457. Antivir. Ther. 11:S37.
3. Kilgore, N., M. Reddick, M. Zuiderhof, F. Li, A. S. Yunus, C. Matallana, D. Zoumplis, A. Castillo, K. Salzwedel, and C. Wild. 2006. The first-in-class maturation inhibitor, PA-457, is a potent inhibitor of HIV-1 drug-resistant isolates and acts synergistically with approved HIV drugs in vitro, poster abstract 509. 13th Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Alexandria, VA.
4. Li, F., R. Goila-Gaur, K. Salzwedel, N. R. Kilgore, M. Reddick, C. Matallana, A. Castillo, D. Zoumplis, D. E. Martin, J. M. Orenstein, G. P. Allaway, E. O. Freed, and C. T. Wild. 2003. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. USA 100:13555-13560.
5. Li, F., D. Zoumplis, C. Matallana, N. R. Kilgore, M. Reddick, A. S. Yunus, C. S. Adamson, K. Salzwedel, D. E. Martin, G. P. Allaway, E. O. Freed, and C. T. Wild. 2006. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 356:217-224.
6. McCallister, S., J. Lalezari, G. Richmond, M. Thompson, R. Harrigan, D. Martin, K. Salzwedel, and G. Allaway. 2008. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Antivir. Ther. 13:A10.
7. Sakalian, M., C. P. McMurtrey, F. J. Deeg, C. W. Maloy, F. Li, C. T. Wild, and K. Salzwedel. 2006. 3-O-(3′,3′-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J. Virol. 80:5716-5722.
8. Salzwedel, K., D. E. Martin, and M. Sakalian. 2007. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 9:162-172.
9. Smith, P. F., A. Ogundele, A. Forrest, J. Wilton, K. Salzwedel, J. Doto, G. P. Allaway, and D. E. Martin. 2007. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 51:3574-3581.
10. Vermeiren, H., E. Van Craenenbroeck, P. Alen, L. Bacheler, G. Picchio, and P. Lecocq. 2007. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J. Virol. Methods 145:47-55.
11. Zhou, J., X. Yuan, D. Dismuke, B. M. Forshey, C. Lundquist, K. H. Lee, C. Aiken, and C. H. Chen. 2004. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J. Virol. 78:922-929.